Rethinking AMR priorities: EVI chairs panel on the targets that move the needle

12 November 2026
Dr Irina Meln, Head of Innovation at the European Vaccine Initiative (EVI), chaired the AMR & Bacterial Vaccines panel, “Rethinking AMR priorities: Choosing the targets that move the needle”, at the World Vaccine Congress 2026 in Amsterdam.

The panel brought together experts from across public health, research and product development, to make the case that vaccines and monoclonal antibodies (mAbs) deserve a larger place in the response to antimicrobial resistance (AMR) in human and animal health.

Panellists noted that AMR vaccines often receive less attention and funding than pandemic preparedness, and that funding for AMR interventions overall remains well below the level called for a decade ago in the O’Neill review, with little directed towards vaccine development.
The panel included Dr Mateusz Hasso-Agopsowicz (World Health Organisation), Dr Flavie Vial (World Organisation for Animal Health), Dr Ankur Mutreja (PATH), Dr Amelia Mosley (International AIDS Vaccine Initiative) and Prof Calman MacLennan (Imperial College London), and highlighted recent progress made on pathogen prioritisation for humans, livestock and fish, promotion of monoclonal antibodies in the Global South as both preventatives and therapeutics, and resource mobilisation toward AMR vaccine licensure.
The panel’s shared message was that the AMR community and policymakers need clear, evidence-backed arguments for the role of vaccines, and that continued cross-sector collaboration will be essential to deliver them.
The panel was convened by Jan Poolman and Isla Sutherland, who also led the AMR conference track.



